Literature DB >> 29484663

Number of nodes in sentinel lymph node biopsy for breast cancer: Are surgeons still biased?

Dean B Percy1, Jin-Si Pao1,2, Elaine McKevitt1, Carol Dingee1,2, Urve Kuusk1,2, Rebecca Warburton1,2.   

Abstract

BACKGROUND AND OBJECTIVES: The purpose of this study was to assess the number of lymph nodes removed at SLNB, and what factors might bias a surgeon's decision to remove additional nodes.
METHODS: A prospectively maintained database was reviewed. All patients that had SLNB for primary treatment of breast cancer between January 2012 and March 2016 were identified. Clinicopathologic factors were used to compare the number of LNs and rates of node positivity.
RESULTS: One thousand six hundred and three patients were included. The average number of SLNs, non-SLNs, and total LNs was 2.53, 0.54, 3.08, respectively. Significantly more LNs were removed in age <40 versus age >40 (3.73, 3.04 P < 0.01), invasive versus DCIS (3.13, 2.73 P < 0.001), Grade III versus Grade II (3.42, 2.99 P < 0.01), T2 versus T1 (3.40, 2.96 P < 0.01), and ER- versus ER+ (3.45, 3.05 P < 0.05). SLN positivity was significantly higher (P < 0.05) in invasive versus DCIS (27%, 4%), T2 versus T1 (30%. 17%), Grade II versus Grade I (42%, 18%), and ILC versus IDC (38%, 26%).
CONCLUSIONS: There was a significant difference in the number of lymph nodes removed at SLNB in certain groups however; node positivity was not necessarily higher in these groups. Surgeons must be cognizant of potential bias when performing SLNB.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  axilla; breast cancer; sentinel lymph node biopsy

Mesh:

Year:  2018        PMID: 29484663     DOI: 10.1002/jso.25010

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  3 in total

1.  Assessment of hospital-level adjusted breast cancer sentinel lymph node positivity rates.

Authors:  Elizabeth R Berger; Karl Y Bilimoria; Christine V Kinnier; Christina A Minami; Kevin P Bethke; Nora M Hansen; Ryan P Merkow; David P Winchester; Anthony D Yang
Journal:  J Surg Oncol       Date:  2018-11-27       Impact factor: 3.454

2.  Sentinel Lymph Node Removal After Neoadjuvant Chemotherapy in Clinically Node-Negative Patients: When to Stop?

Authors:  Brittany L Murphy; James W Jakub; Malke Asaad; Courtney N Day; Tanya L Hoskin; Elizabeth B Habermann; Judy C Boughey
Journal:  Ann Surg Oncol       Date:  2020-08-20       Impact factor: 5.344

3.  Comparison of four lymph node staging systems for predicting prognosis for stage IV rectum cancer.

Authors:  Lingyu Han; Shaobo Mo; Wenqiang Xiang; Qingguo Li; Renjie Wang; Ye Xu; Weixing Dai; Guoxiang Cai
Journal:  Ann Transl Med       Date:  2020-02
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.